Literature DB >> 2433403

Somatostatin-like immunoreactivity in the cerebrospinal fluid of patients with Parkinson's disease and its relation to dementia.

J Jolkkonen, H Soininen, T Halonen, A Ylinen, V Laulumaa, M Laakso, P Riekkinen.   

Abstract

Acetylcholinesterase, somatostatin-like immunoreactivity, and homovanillic acid levels were measured in the cerebrospinal fluid of 36 patients with early stages of Parkinson's disease and in 19 control patients. In patients with Parkinson's disease the levels of somatostatin-like immunoreactivity were lower than in the controls (p less than 0.01); these values were lowest in the demented Parkinsonian patients. Concentrations of homovanillic acid were also significantly lower in Parkinsonian patients (p less than 0.05). In contrast, no changes were observed in the acetylcholinesterase activity of patients with Parkinson's disease. The reduced somatostatin-like immunoreactivity in CSF agrees with previous post-mortem studies and indicates that Parkinson's disease and Alzheimer's disease may have some neurochemical features in common.

Entities:  

Mesh:

Substances:

Year:  1986        PMID: 2433403      PMCID: PMC1029121          DOI: 10.1136/jnnp.49.12.1374

Source DB:  PubMed          Journal:  J Neurol Neurosurg Psychiatry        ISSN: 0022-3050            Impact factor:   10.154


  24 in total

1.  A new and rapid colorimetric determination of acetylcholinesterase activity.

Authors:  G L ELLMAN; K D COURTNEY; V ANDRES; R M FEATHER-STONE
Journal:  Biochem Pharmacol       Date:  1961-07       Impact factor: 5.858

2.  A rating scale for depression.

Authors:  M HAMILTON
Journal:  J Neurol Neurosurg Psychiatry       Date:  1960-02       Impact factor: 10.154

3.  Decreased CSF acetylcholinesterase activity in Alzheimer's disease.

Authors:  M E Appleyard; A D Smith; G K Wilcock; M M Esiri
Journal:  Lancet       Date:  1983-08-20       Impact factor: 79.321

4.  Reduced cholinesterase activity and somatostatin-like immunoreactivity in the cerebrospinal fluid of patients with dementia of the Alzheimer type.

Authors:  H S Soininen; J T Jolkkonen; K J Reinikainen; T O Halonen; P J Riekkinen
Journal:  J Neurol Sci       Date:  1984-02       Impact factor: 3.181

5.  Neurochemical basis of dementia in Parkinson's disease.

Authors:  O Hornykiewicz; S J Kish
Journal:  Can J Neurol Sci       Date:  1984-02       Impact factor: 2.104

6.  A subcortico-cortical cholinergic system is affected in Parkinson's disease.

Authors:  B Dubois; M Ruberg; F Javoy-Agid; A Ploska; Y Agid
Journal:  Brain Res       Date:  1983-12-12       Impact factor: 3.252

7.  Methionine-enkephalin, substance P, and homovanillic acid in the CSF of parkinsonian patients.

Authors:  G Pezzoli; A E Panerai; A Di Giulio; A Longo; D Passerini; A Carenzi
Journal:  Neurology       Date:  1984-04       Impact factor: 9.910

8.  Somatostatin and dementia in Parkinson's disease.

Authors:  J Epelbaum; M Ruberg; E Moyse; F Javoy-Agid; B Dubois; Y Agid
Journal:  Brain Res       Date:  1983-11-14       Impact factor: 3.252

9.  CSF somatostatin in affective illness.

Authors:  D R Rubinow; P W Gold; R M Post; J C Ballenger; R Cowdry; J Bollinger; S Reichlin
Journal:  Arch Gen Psychiatry       Date:  1983-04

10.  How common is dementia in Parkinson's disease?

Authors:  R G Brown; C D Marsden
Journal:  Lancet       Date:  1984-12-01       Impact factor: 79.321

View more
  7 in total

1.  Cholinesterases in the cerebrospinal fluid, plasma, and erythrocytes of patients with Alzheimer's disease.

Authors:  J Sirviö; R Kutvonen; H Soininen; P Hartikainen; P J Riekkinen
Journal:  J Neural Transm       Date:  1989       Impact factor: 3.575

2.  A long-term follow-up study of cerebrospinal fluid acetylcholinesterase in delirium.

Authors:  H J Koponen; J Sirviö; U Lepola; E Leinonen; P J Riekkinen
Journal:  Eur Arch Psychiatry Clin Neurosci       Date:  1994       Impact factor: 5.270

3.  Somatostatin-like immunoreactivity, its molecular forms and monoaminergic metabolites in aged and demented patients with Parkinson's disease--effect of L-Dopa.

Authors:  M Strittmatter; G F Hamann; D Strubel; H Cramer; K Schimrigk
Journal:  J Neural Transm (Vienna)       Date:  1996       Impact factor: 3.575

4.  Diffuse Lewy body disease. Neuropathological and biochemical studies of six patients.

Authors:  D W Dickson; P Davies; R Mayeux; H Crystal; D S Horoupian; A Thompson; J E Goldman
Journal:  Acta Neuropathol       Date:  1987       Impact factor: 17.088

5.  Diffuse Lewy body disease: light and electron microscopic immunocytochemistry of senile plaques.

Authors:  D W Dickson; H Crystal; L A Mattiace; Y Kress; A Schwagerl; H Ksiezak-Reding; P Davies; S H Yen
Journal:  Acta Neuropathol       Date:  1989       Impact factor: 17.088

Review 6.  Cerebrospinal fluid biochemical studies in patients with Parkinson's disease: toward a potential search for biomarkers for this disease.

Authors:  Félix J Jiménez-Jiménez; Hortensia Alonso-Navarro; Elena García-Martín; José A G Agúndez
Journal:  Front Cell Neurosci       Date:  2014-11-11       Impact factor: 5.505

Review 7.  Diagnostic cerebrospinal fluid biomarkers for Parkinson's disease: a pathogenetically based approach.

Authors:  Karin D van Dijk; Charlotte E Teunissen; Benjamin Drukarch; Connie R Jimenez; Henk J Groenewegen; Henk W Berendse; Wilma D J van de Berg
Journal:  Neurobiol Dis       Date:  2010-05-06       Impact factor: 5.996

  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.